Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 36108661

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Oct
First author
Subbiah V

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Oct;23(10):1235-1237. doi: 10.1016/S1470-2045(22)00556-3.
    note
    Source null
    related pmid
    36108663
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Dec;19(12):747. doi: 10.1038/s41571-022-00694-2.
    note
    Source null
    related pmid
    36207414
    relationship
    Comment in

Authors and identifiers

  1. name
    Subbiah V
    type
    Author
  2. name
    Wolf J
    type
    Author
  3. name
    Konda B
    type
    Author
  4. name
    Kang H
    type
    Author
  5. name
    Spira A
    type
    Author
  6. name
    Weiss J
    type
    Author
  7. name
    Takeda M
    type
    Author
  8. name
    Ohe Y
    type
    Author
  9. name
    Khan S
    type
    Author
  10. name
    Ohashi K
    type
    Author
  11. name
    Soldatenkova V
    type
    Author
  12. name
    Szymczak S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Subbiah V
    type
    Author
  2. name
    Wolf J
    type
    Author
  3. name
    Konda B
    type
    Author
  4. name
    Kang H
    type
    Author
  5. name
    Spira A
    type
    Author
  6. name
    Weiss J
    type
    Author
  7. name
    Takeda M
    type
    Author
  8. name
    Ohe Y
    type
    Author
  9. name
    Khan S
    type
    Author
  10. name
    Ohashi K
    type
    Author
  11. name
    Soldatenkova V
    type
    Author
  12. name
    Szymczak S
    type
    Author
bibliography ids
  1. nci-bib-a62312d453ab49bc3b12b9d6
book metadata
content sha256
246b50dd068ccaa602b4bf48a3bfc9d368740845fb74de927384aa6fc10bbe43
document type
citation
dois
  1. 10.1016/S1470-2045(22)00541-1
electronic publication date
display
2022 Sep 12
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36108661
immutable id
pubmed:36108661@246b50dd068ccaa602b4bf48a3bfc9d368740845fb74de927384aa6fc10bbe43
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1261-1273
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Oct;23(10):1235-1237. doi: 10.1016/S1470-2045(22)00556-3.
    note
    Source null
    related pmid
    36108663
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Dec;19(12):747. doi: 10.1038/s41571-022-00694-2.
    note
    Source null
    related pmid
    36207414
    relationship
    Comment in
outcomes validated
false
pmid
36108661
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
e93e0554dba5050c0ca93364418ca41d700fc22b3d9d8d5d1da13f856029f059
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Oct
precision
month
year
2022
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36108661/
title
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.

Preserved source evidence · Independent clinical review pending · Not medical advice